|
Erie
Wednesday, March 19, 2003: 4:00 PM-5:30 PM |
F7: An Overview of the Anthrax Vaccine and Antibiotic Availability Program and Future Directions for Anthrax Vaccine Adverse Event Surveillance |
| This workshop will provide a review of CDC’s Anthrax Vaccine and Antibiotic Availability Program (AVAAP) which was implemented to allow for further post-exposure prophylaxis for persons at high risk for inhalational anthrax following the intentional release of B. anthracis in the Fall of 2001. Additionally, the workshop will focus on the surveillance mechanisms for adverse events in the AVAAP and an overview of the serious adverse events (SAEs) reported will be presented. This session will also describe a collaborative effort to use a large linked surveillance database to investigate the occurrence of anthrax vaccine adverse events in the military population. |
Learning Objectives: Participants will be able to describe a public health response to provide post-exposure prophylaxis in the setting of an intentional release of B. anthracis spores, recognize the low rate of SAEs associated with the AVAAP and understand surveillance mechanisms for SAEs in a post-exposure prophylaxis public health response program to bioterrorism, and understand the use of a large-linked database for the investigation of vaccine associated adverse events.
|
| Moderator: | Michael McNeil |
| 4:00 PM | | Introductory Remarks
|
| 4:05 PM | | Presentation — Stacey Martin
|
| 4:25 PM | 2011 | Serious Adverse Events among Participants in CDC’s Anthrax Vaccine and Antimicrobial Availability Program for Persons at Risk for Bioterrorism-Related Inhalational Anthrax
Bruce C. Tierney, Stacey W. Martin, Laura H. Franzke, Nina Marano, Dori B. Reissman, Randy D. Louchart, Joyce A. Goff, Nancy E. Rosenstein, John L. Sever, Michael M. McNeil |
| 4:45 PM | | Presentation — Laura Franzke
|
| 5:05 PM | | Discussion
|
